In addition, PROS1 was found significantly increased in WHO IV, IDH-wildtype, and 1p/19q no-codeletion glioma patients in the CGGA cohort (id mRNA-seq_325) (Figures 7I–K). This evidence concerns the gene PROS1 and central nervous system cancer.